
Opinion|Videos|September 19, 2024
WCLC 2024: Analyzing SKIPPirr Data Outcomes for Lung Cancer Advancements
Panelists discuss how the SKIPPirr data outcomes presented at World Conference for Lung Cancer 2024 provide valuable insights into the potential use of amivantamab for advancing lung cancer treatment strategies.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5








































